GlaxoSmithKline plc 11.2% Potential Upside Indicated by Oddo

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ this morning by analysts at Oddo. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Oddo have set a target price of 1840 GBX on its stock. This is indicating the analyst believes there is a potential upside of 11.2% from today’s opening price of 1654.2 GBX. Over the last 30 and 90 trading days the company share price has increased 5.8 points and increased 245 points respectively. The 52 week high for the share price is currently at 1857 GBX while the year low stock price is currently 1328.19 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,677.71 GBX and a 200 Day Moving Average share price is recorded at 1,697.79. There are currently 5,017,173,654 shares in issue with the average daily volume traded being 9,372,116. Market capitalisation for LON:GSK is £83,716,558,365 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
    GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.
    GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic.
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.

      Search

      Search